Jesús
Corral Jaime
Ikertzailea 2022-(e)ra arte
Dana–Farber Cancer Institute
Boston, Estados UnidosDana–Farber Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2017
-
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease
Clinical Lung Cancer, Vol. 18, Núm. 1, pp. 68-76.e2